ERAS ERASCA INC

Erasca to Present at Upcoming Conferences in November

Erasca to Present at Upcoming Conferences in November

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences in November 2025 and will also participate in one-on-one investor meetings at each of these conferences.

Guggenheim 2nd Annual Healthcare Innovation Conference (November 10-12, 2025)

Location: Boston, MA

Format: Fireside Chat

Date and Time: Tuesday, November 11, 2:00 pm Eastern Time

Stifel 2025 Healthcare Conference (November 11-13, 2025)

Location: New York, NY

Format: Fireside Chat

Date and Time: Wednesday, November 12, 1:20 pm Eastern Time

Jefferies Global Healthcare Conference (November 17-20, 2025)

Location: London, UK

Format: Fireside Chat

Date and Time: Wednesday, November 19, 10:30 am Greenwich Mean Time

A live audio webcast of the events will be available online at . An archived replay of the events will be available for 30 days following the webcast at .

About Erasca

At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.

Contact:

Joyce Allaire

LifeSci Advisors, LLC



EN
04/11/2025

Underlying

ERASERASCA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ERASCA INC

 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Closing of Upsized Public Offering of Common Stock, I...

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has closed its previously announced upsized public offering of 25,875,000 shares of its common stock, including 3,375,000 shares sold pursuant to the underwriters’ full exercise ...

January 23, 2026 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca Announces Pricing of Upsized Public Offering of Common Stock SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. The shares of common stock are being sold to the public at a price of $10.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca....

January 22, 2026 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Proposed Public Offering of $150 Million of Common St...

Erasca Announces Proposed Public Offering of $150 Million of Common Stock SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in a proposed underwritten public offering. All of the shares of common stock to be sold in the proposed offering are being offered by Eras...

January 20, 2026 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-...

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones Encouraging early clinical activity, including confirmed partial responses in multiple tumor types with different RAS mutations, coupled with promising safety and pharmacokinetics data, observed for ERAS-0015 during dose escalation Initial Phase 1 monotherapy data for ERAS-0015 (potential best-in-class pan-RAS molecular glue) planned for H1 2026 and for ERAS-4001 (potential first-in-class pan-KRAS inhibitor) planned for H2 2026 SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a...

January 12, 2026 1 EN
 PRESS RELEASE
Free
ERAS ERASCA INC

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis in San Francisco, California. Management will present on Tuesday, January 13, 2026, at 1:30 pm Pacific Time and will also participate in one-on-one invest...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch